Alerts will be sent to your verified email
Verify EmailGLENMARK
Glenmark Pharma
|
Ipca Laboratories
|
Ajanta Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
13.0 . | 43.0 . | 74.0 . |
Number of ANDA's Approved By USFDA
|
25.0 . | 21.0 . | 53.0 . |
Domestic Sales Growth - YoY
|
10.1 % | 7.6 % | 15.6 % |
R&D as a % of Total Sales
|
6.6 % | 2.64 % | 5.0 % |
Financials
|
|||
5 yr Average ROE
|
4.18 % | 14.77 % | 20.38 % |
5yr average Equity Multiplier
|
1.88 | 1.47 | 1.34 |
5yr Average Asset Turnover Ratio
|
0.79 | 0.79 | 0.79 |
5yr Avg Net Profit Margin
|
2.73 % | 12.85 % | 19.43 % |
Price to Book
|
4.61 | 5.29 | 8.9 |
P/E
|
0.0 | 48.57 | 36.66 |
5yr Avg Cash Conversion Cycle
|
-121.67 Days | 62.7 Days | -93.41 Days |
Inventory Days
|
40.44 Days | 101.09 Days | 61.2 Days |
Days Receivable
|
36.38 Days | 63.37 Days | 52.69 Days |
Days Payable
|
201.37 Days | 112.44 Days | 198.04 Days |
5yr Average Interest Coverage Ratio
|
3.48 | 55.69 | 108.17 |
5yr Avg ROCE
|
16.29 % | 18.16 % | 25.98 % |
5yr Avg Operating Profit Margin
|
15.62 % | 19.9 % | 27.51 % |
5 yr average Debt to Equity
|
0.49 | 0.16 | 0.0 |
5yr CAGR Net Profit
|
n/a | -2.03 % | 11.78 % |
5yr Average Return on Assets
|
1.86 % | 10.46 % | 15.32 % |
Shareholdings
|
|||
Promoter Holding
|
46.65 % | 44.72 % | 66.26 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 12.61 % |
Change in Promoter Holding (3 Yrs)
|
0.0 | -1.57 % | -4.22 % |
Change in Mutual Fund Holding (3 Yrs)
|
6.68 % | 1.43 % | 4.63 % |
Glenmark Pharma
|
Ipca Laboratories
|
Ajanta Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|
Asset Break-Up
|